Suchergebnisse - "Kazandjian, Dickran"

PubPharm (95)

31

Managing multiple myeloma in a resource-limited region : Diagnosis and treatment in Armenia

enthalten in: Seminars in oncology | 2021

von Oganesyan, A. | Ghahramanyan, N. | Mekinian, A. | +3

32

Diagnostic performance of 18 F-FDG-PET/CT compared to standard skeletal survey for detecting bone destruction in smouldering multiple myeloma : time to move forward

enthalten in: British journal of haematology | 2021

von Hill, E. | Mena, E. | Morrison, C. | +4

33

Avelumab, a PD-L1 Inhibitor, in Combination with Hypofractionated Radiotherapy and the Abscopal Effect in Relapsed Refractory Multiple Myeloma

enthalten in: The oncologist | 2021

von Kazandjian, D. | Dew, A. | Hill, E. | +19

34

Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities

enthalten in: Nature communications | 2021

von Oben, B. | Froyen, G. | Maclachlan, K. | +24

35

Incidence patterns and review of Hodgkin lymphoma in the Republic of Armenia

enthalten in: Ecancermedicalscience | 2021

von Arakelyan, J. | Movsisyan, A. | Sargsyan, L. | +11

36

Assessment of Discordance Among Smoldering Multiple Myeloma Risk Models

enthalten in: JAMA oncology | 2021

von Hill, E. | Dew, A. | Morrison, C. | +4

37

Avelumab, a PD‐L1 Inhibitor, in Combination with Hypofractionated Radiotherapy and the Abscopal Effect in Relapsed Refractory Multiple Myeloma

enthalten in: The oncologist | 2021

von Kazandjian, D. | Dew, A. | Hill, E. | +19

38

Treatments for newly diagnosed multiple myeloma : when endurance is interrupted

enthalten in: The Lancet. Oncology | 2020

von Landgren, O. | Siegel, D. | Kazandjian, D. | +2

CommentOn: Lancet Oncol. 2020 Oct;21(10):1317-1330. - PMID 32866432

39

The role of high-dose melphalan with autologous stem-cell transplant in multiple myeloma : is it time for a paradigm shift?

enthalten in: British journal of haematology | 2020

von Kazandjian, D. | Mo, C. | Landgren, O. | +1

40

Differentiation Syndrome with Ivosidenib and Enasidenib Treatment in Patients with Relapsed or Refractory IDH-Mutated AML : A U.S. Food and Drug Administration Systematic Analysis

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2020

von Norsworthy, K. | Mulkey, F. | Scott, E. | +11

CommentIn: Clin Cancer Res. 2020 Aug 15;26(16):4174-4176. - PMID 32554513